VCX3A

Across TCGA pan-cancer cohorts, VCX3A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated VCX3A data layer compared with 17 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher VCX3A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated VCX3A expression acts as an unfavorable survival marker.

STAD and UCEC are the cancer types where VCX3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.113	0.711	<.001	24	view →
UCEC	DFS	Median	III,IV	0.176	0.702	.004	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

VCX3A–STAD (OS)

Open the STAD breakdown →